Overall survival by chemo‐/radiotherapy ‐ Chemotherapy only · resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus
Perioperative chemotherapy leads to lower overall survival by chemo‐/radiotherapy ‐ Chemotherapy only compared with primary surgery (high certainty).
1 finding from 1 review
All‐cause mortality at 5 years · people with resectable cholangiocarcinoma
It is very uncertain whether adjuvant chemotherapy changes all‐cause mortality at 5 years compared with no chemotherapy (very low certainty).
1 finding from 1 review
Serious adverse events · people with resectable cholangiocarcinoma
It is very uncertain whether adjuvant chemotherapy changes serious adverse events compared with no chemotherapy (very low certainty).
1 finding from 1 review
Health‐related quality of life · people with resectable cholangiocarcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Cancer‐related mortality at maximal · people with resectable cholangiocarcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time to recurrence · people with resectable cholangiocarcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Non‐serious adverse events · people with resectable cholangiocarcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall survival† · people with cutaneous melanoma
Biochemotherapy showed no clear difference in overall survival† compared with chemotherapy (high certainty).
1 finding from 1 review
HR 0.94 [0.84, 1.06]
1317 participants
High
Progression‐free survival · people with cutaneous melanoma
Biochemotherapy leads to lower progression‐free survival† compared with chemotherapy (high certainty).
1 finding from 1 review
HR 0.9 [0.83, 0.99]
964 participants
High
Tumour response · people with cutaneous melanoma
Biochemotherapy leads to higher tumour response compared with chemotherapy (high certainty).
1 finding from 1 review
RR 1.36 [1.12, 1.66]
770 participants
High
Toxicity (≥ G3) · people with cutaneous melanoma
Biochemotherapy leads to higher toxicity (≥ G3) compared with chemotherapy (high certainty).
1 finding from 1 review
RR 1.35 [1.14, 1.61]
631 participants
High
Overall survival at 5‐year · women with early poor prognosis breast cancer
High‐dose chemotherapy showed no clear difference in overall survival at 5‐year compared with chemotherapy without bone marrow transplant or stem cell rescue (high certainty).
1 finding from 1 review
Event‐free survival · women with early poor prognosis breast cancer
High‐dose chemotherapy showed no clear difference in event‐free survival at 5‐year compared with chemotherapy without bone marrow transplant or stem cell rescue (high certainty).
1 finding from 1 review
Treatment‐related mortality · women with early poor prognosis breast cancer
High‐dose chemotherapy leads to higher treatment‐related mortality compared with chemotherapy without bone marrow transplant or stem cell rescue (high certainty).
1 finding from 1 review
Second cancers at 4 ‐ 9‐year median · women with early poor prognosis breast cancer
High‐dose chemotherapy showed no clear difference in second cancers at 4 ‐ 9‐year median compared with chemotherapy without bone marrow transplant or stem cell rescue (high certainty).
1 finding from 1 review
Overall survival† · people with cutaneous melanoma
Polychemotherapy showed no clear difference in overall survival† compared with chemotherapy (high certainty).
1 finding from 1 review
HR 0.99 [0.85, 1.16]
594 participants
High
Progression‐freesurvival† · people with cutaneous melanoma
Polychemotherapy showed no clear difference in progression‐freesurvival† compared with chemotherapy (high certainty).
1 finding from 1 review
HR 1.07 [0.91, 1.25]
398 participants
High
Tumour response · people with cutaneous melanoma
Polychemotherapy probably leads to higher tumour response compared with chemotherapy (moderate certainty).
1 finding from 1 review
RR 1.27 [1.02, 1.58]
1885 participants
Moderate
Toxicity (≥ G3) · people with cutaneous melanoma
Polychemotherapy probably leads to higher toxicity (≥ G3) compared with chemotherapy (moderate certainty).
1 finding from 1 review
RR 1.97 [1.44, 2.71]
390 participants
Moderate
Overall survival (3 years) · people with resectable stage II and III rectal cancer undergoing preoperative chemoradiation followed by surgery
It is very uncertain whether combination chemotherapy changes overall survival (3 years) compared with single‐agent chemotherapy (very low certainty).
1 finding from 1 review